(Q38497683)

3 September 2017

1 reference

title

Sitagliptin for Type 2 diabetes: a 2015 update (English)

1 reference

3 September 2017

1 reference

Maria Lee

1

1 reference

3 September 2017

Mary K Rhee

series ordinal

2

1 reference

3 September 2017

publication date

1 June 2015

1 reference

Expert Review of Cardiovascular Therapy

3 September 2017

published in

1 reference

3 September 2017

volume

13

1 reference

3 September 2017

issue

6

1 reference

3 September 2017

page(s)

597-610

1 reference

The essential role of glucagon in the pathogenesis of diabetes mellitus

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Glucagon and type 2 diabetes: the return of the alpha cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Cardiovascular effects of glucagonlike peptide-1 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Advances in understanding the expression and function of dipeptidyl peptidase 8 and 9

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Sitagliptin and the risk of hospitalization for heart failure: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Real-world effectiveness of sitagliptin as add-on therapy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2015.1046840

10.1586/14779072.2015.1046840

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference